- Home
- RPRX vs NDSN Comparison
RPRX vs NDSN Comparison
Compare RPRX & NDSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- NDSN
- Stock Information
- Founded
- RPRX 1996
- NDSN 1935
- Country
- RPRX United States
- NDSN United States
- Employees
- RPRX N/A
- NDSN N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- NDSN Industrial Machinery/Components
- Sector
- RPRX Health Care
- NDSN Industrials
- Exchange
- RPRX Nasdaq
- NDSN Nasdaq
- Market Cap
- RPRX 14.2B
- NDSN 12.0B
- IPO Year
- RPRX 2020
- NDSN N/A
- Fundamental
- Price
- RPRX $31.13
- NDSN $201.72
- Analyst Decision
- RPRX Strong Buy
- NDSN Strong Buy
- Analyst Count
- RPRX 5
- NDSN 5
- Target Price
- RPRX $41.60
- NDSN $262.40
- AVG Volume (30 Days)
- RPRX 4.3M
- NDSN 307.7K
- Earning Date
- RPRX 05-08-2025
- NDSN 05-19-2025
- Dividend Yield
- RPRX 2.83%
- NDSN 1.54%
- EPS Growth
- RPRX N/A
- NDSN N/A
- EPS
- RPRX 1.91
- NDSN 7.86
- Revenue
- RPRX $2,263,576,000.00
- NDSN $2,672,148,000.00
- Revenue This Year
- RPRX $33.46
- NDSN $5.02
- Revenue Next Year
- RPRX $4.44
- NDSN $4.88
- P/E Ratio
- RPRX $16.28
- NDSN $25.82
- Revenue Growth
- RPRX N/A
- NDSN 0.79
- 52 Week Low
- RPRX $24.05
- NDSN $196.83
- 52 Week High
- RPRX $34.20
- NDSN $279.38
- Technical
- Relative Strength Index (RSI)
- RPRX 33.61
- NDSN 39.58
- Support Level
- RPRX $32.26
- NDSN $203.73
- Resistance Level
- RPRX $34.14
- NDSN $209.89
- Average True Range (ATR)
- RPRX 0.76
- NDSN 4.58
- MACD
- RPRX -0.33
- NDSN -0.28
- Stochastic Oscillator
- RPRX 14.00
- NDSN 31.53
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.